Hansa Grows Cash Pile Ahead of Idefirix US Filing

European Launches Progressing Smoothly

 
• By Kevin Grogan

The Swedish biotech has added another $40m to its coffers as it advances its potential ‘pipeline in a product’ for kidney disease.

Hansa keen to be a leader in kidney disease • Source: Shutterstock

More from Financing

More from Business